期刊
LANCET RHEUMATOLOGY
卷 4, 期 1, 页码 E33-E41出版社
ELSEVIER
DOI: 10.1016/S2665-9913(21)00325-8
关键词
-
类别
资金
- National Heart, Lung and Blood Institute Pharmacoepidemiology T32 Training Program [T32HL139426]
- Clinical and Translational Science Award from NCATS [UL1TR002649]
- NCATS [UL1TR003096, U24 TR002306]
- NIH National Institute of Allergy and Infectious Diseases [K23AI120855]
- National Institute on Aging [1K01AG070329]
This study found that the use of immunosuppressive medications in hospitalized COVID-19 patients was associated with a reduced risk of invasive ventilation, but overall no association with in-hospital death. Some medication classes may be associated with an increased risk of death for specific diseases, such as rituximab for rheumatological disease and cancer. Careful medication selection is needed for COVID-19 patients with long-term immunosuppression.
Background Many individuals take long-term immunosuppressive medications. We evaluated whether these individuals have worse outcomes when hospitalised with COVID-19 compared with non-immunosuppressed individuals. Methods We conducted a retrospective cohort study using data from the National COVID Cohort Collaborative (N3C), the largest longitudinal electronic health record repository of patients in hospital with confirmed or suspected COVID-19 in the USA, between Jan 1, 2020, and June 11, 2021, within 42 health systems. We compared adults with immunosuppressive medications used before admission to adults without long-term immunosuppression. We considered immunosuppression overall, as well as by 15 classes of medication and three broad indications for immunosuppressive medicines. We used Fine and Gray's proportional subdistribution hazards models to estimate the hazard ratio (HR) for the risk of invasive mechanical ventilation, with the competing risk of death. We used Cox proportional hazards models to estimate HRs for in-hospital death. Models were adjusted using doubly robust propensity score methodology. Findings Among 231 830 potentially eligible adults in the N3C repository who were admitted to hospital with confirmed or suspected COVID-19 during the study period, 222 575 met the inclusion criteria (mean age 59 years [SD 19]; 111 269 [50%] male). The most common comorbidities were diabetes (23%), pulmonary disease (17%), and renal disease (13%). 16 494 (7%) patients had long-term immunosuppression with medications for diverse conditions, including rheumatological disease (33%), solid organ transplant (26%), or cancer (22%). In the propensity score matched cohort (including 12 841 immunosuppressed patients and 29 386 non-immunosuppressed patients), immunosuppression was associated with a reduced risk of invasive ventilation (HR 0middot89, 95% CI 0middot83-0middot96) and there was no overall association between long-term immunosuppression and the risk of in-hospital death. None of the 15 medication classes examined were associated with an increased risk of invasive mechanical ventilation. Although there was no statistically significant association between most drugs and in-hospital death, increases were found with rituximab for rheumatological disease (1middot72, 1middot10-2middot69) and for cancer (2middot57, 1middot86-3middot56). Results were generally consistent across subgroup analyses that considered race and ethnicity or sex, as well as across sensitivity analyses that varied exposure, covariate, and outcome definitions. Interpretation Among this cohort, with the exception of rituximab, there was no increased risk of mechanical ventilation or in-hospital death for the rheumatological, antineoplastic, or antimetabolite therapies examined. Funding None. Copyright (c) 2021 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据